These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
7. Oritavancin: a novel lipoglycopeptide active against Gram-positive pathogens including multiresistant strains. Bouza E; Burillo A Int J Antimicrob Agents; 2010 Nov; 36(5):401-7. PubMed ID: 20729040 [TBL] [Abstract][Full Text] [Related]
8. Oritavancin: a new promising agent in the treatment of infections due to Gram-positive pathogens. Poulakou G; Giamarellou H Expert Opin Investig Drugs; 2008 Feb; 17(2):225-43. PubMed ID: 18230056 [TBL] [Abstract][Full Text] [Related]
9. Oritavancin: a new avenue for resistant Gram-positive bacteria. Mercier RC; Hrebickova L Expert Rev Anti Infect Ther; 2005 Jun; 3(3):325-32. PubMed ID: 15954849 [TBL] [Abstract][Full Text] [Related]
10. Oritavancin: a potential weapon in the battle against serious Gram-positive pathogens. Crandon J; Nicolau DP Future Microbiol; 2008 Jun; 3(3):251-63. PubMed ID: 18505390 [TBL] [Abstract][Full Text] [Related]
11. Single-dose oritavancin versus 7-10 days of vancomycin in the treatment of gram-positive acute bacterial skin and skin structure infections: the SOLO II noninferiority study. Corey GR; Good S; Jiang H; Moeck G; Wikler M; Green S; Manos P; Keech R; Singh R; Heller B; Bubnova N; O'Riordan W; Clin Infect Dis; 2015 Jan; 60(2):254-62. PubMed ID: 25294250 [TBL] [Abstract][Full Text] [Related]
12. Oritavancin: an investigational lipoglycopeptide antibiotic. Karaoui LR; El-Lababidi R; Chahine EB Am J Health Syst Pharm; 2013 Jan; 70(1):23-33. PubMed ID: 23261897 [TBL] [Abstract][Full Text] [Related]
14. Pooled analysis of single-dose oritavancin in the treatment of acute bacterial skin and skin-structure infections caused by Gram-positive pathogens, including a large patient subset with methicillin-resistant Staphylococcus aureus. Corey GR; Arhin FF; Wikler MA; Sahm DF; Kreiswirth BN; Mediavilla JR; Good S; Fiset C; Jiang H; Moeck G; Kabler H; Green S; O'Riordan W; Int J Antimicrob Agents; 2016 Nov; 48(5):528-534. PubMed ID: 27665522 [TBL] [Abstract][Full Text] [Related]
15. Dalbavancin and Oritavancin: An Innovative Approach to the Treatment of Gram-Positive Infections. Roberts KD; Sulaiman RM; Rybak MJ Pharmacotherapy; 2015 Oct; 35(10):935-48. PubMed ID: 26497480 [TBL] [Abstract][Full Text] [Related]
17. Oritavancin for skin infections. Anderson DL Drugs Today (Barc); 2008 Aug; 44(8):563-75. PubMed ID: 18846268 [TBL] [Abstract][Full Text] [Related]
18. Glycopeptides in clinical development: pharmacological profile and clinical perspectives. Van Bambeke F Curr Opin Pharmacol; 2004 Oct; 4(5):471-8. PubMed ID: 15351351 [TBL] [Abstract][Full Text] [Related]
19. Use of in vitro vancomycin testing results to predict susceptibility to oritavancin, a new long-acting lipoglycopeptide. Jones RN; Turnidge JD; Moeck G; Arhin FF; Mendes RE Antimicrob Agents Chemother; 2015 Apr; 59(4):2405-9. PubMed ID: 25666152 [TBL] [Abstract][Full Text] [Related]